MediciNova (NASDAQ:MNOV) Share Price Crosses Above Two Hundred Day Moving Average – Here’s Why

MediciNova, Inc. (NASDAQ:MNOV)’s stock price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.44 and traded as high as $1.4444. MediciNova shares last traded at $1.43, with a volume of 21,106 shares.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on MNOV shares. Maxim Group reissued a “buy” rating and set a $6.00 price target on shares of MediciNova in a research note on Monday, March 23rd. HC Wainwright initiated coverage on shares of MediciNova in a report on Monday, March 16th. They set a “buy” rating and a $10.00 target price for the company. Zacks Research upgraded shares of MediciNova to a “hold” rating in a research report on Tuesday, March 17th. D. Boral Capital reissued a “buy” rating and issued a $9.00 price target on shares of MediciNova in a research note on Friday, January 30th. Finally, Lucid Cap Mkts upgraded MediciNova to a “strong-buy” rating in a research report on Monday, January 5th. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, MediciNova presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.50.

MediciNova Trading Up 1.4%

The company has a market capitalization of $70.39 million, a P/E ratio of -5.96 and a beta of 0.61. The business has a 50 day moving average price of $1.46 and a 200 day moving average price of $1.44.

MediciNova (NASDAQ:MNOV) last issued its quarterly earnings data on Friday, February 20th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.05. The firm had revenue of $0.15 million for the quarter. On average, analysts forecast that MediciNova, Inc. will post -0.24 EPS for the current fiscal year.

Institutional Trading of MediciNova

A number of large investors have recently made changes to their positions in MNOV. State Street Corp lifted its holdings in MediciNova by 10.9% during the fourth quarter. State Street Corp now owns 193,698 shares of the biopharmaceutical company’s stock worth $254,000 after acquiring an additional 19,100 shares in the last quarter. StoneX Group Inc. bought a new stake in shares of MediciNova in the fourth quarter worth about $25,000. Goldman Sachs Group Inc. bought a new stake in shares of MediciNova in the fourth quarter worth about $35,000. Citadel Advisors LLC acquired a new stake in shares of MediciNova during the third quarter worth about $92,000. Finally, Jane Street Group LLC acquired a new stake in shares of MediciNova during the fourth quarter worth about $214,000. Institutional investors own 9.90% of the company’s stock.

About MediciNova

MediciNova, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule therapeutics for neurodegenerative, inflammatory, fibrotic and oncological diseases. Founded in the late 1990s, the company advances its proprietary compounds through clinical trials and strategic partnerships, with a goal of addressing areas of high unmet medical need. MediciNova is headquartered in San Diego, California, and maintains a presence in Tokyo to support collaborations and regulatory interactions in Asian markets.

The company’s leading clinical asset, MN-166 (ibudilast), is an anti-inflammatory and neuroprotective agent originally approved in Japan for asthma and post-stroke dizziness.